The prognostic importance of genetic information in primary myelofibrosis (PMF) was recently highlighted in a study of over 1000 cytogenetically-annotated patients; 5-year survival rates were 8% for very high risk (VHR), 27% "unfavorable" and 45% "favorable" karyotype. The current study addresses the practice-relevant question of whether or not allogeneic hematopoietic stem cell transplant (HCT) can overcome the detrimental survival effect of VHR or unfavorable karyotype.
(1.6-3.6) for absence of transplant, 3.3 (2.2-4.8) for VHR karyotype, 1.6 (1.2-2.1) for unfavorable karyotype, 2.9 (2.0-4.2) for DIPSS high and 1.7 (1.4-2.2) for DIPSS intermediate-2. These observations were further confirmed by analysis of more stringently matched case-control subset cohorts and provide the evidence for the therapeutic preference of HCT in cytogenetically high risk patients with MF.
| I N TR ODU C TI ON
Current drug therapy in myelofibrosis (MF) has not been shown to produce morphologic, cytogenetic or molecular remissions and is marred by both short-term and long-term toxicities 1, 2 ; allogeneic hematopoietic stem cell transplantation (HCT) offers the only chance for cure or prolongation of survival. 3, 4 The decision to pursue HCT or a Survival data in transplant patients were compared to those of two separate nontransplant control groups; "control group A" (n 5 383) was selected from a larger database of PMF patients seen within the time frame of transplant dates and broadly matched with the transplant cohort by excluding patients older than the upper age limit for the transplant group and DIPSS low risk disease. "Control group B" (n 5 56) represents a more stringent matching process where 56 controls were successfully matched with each of 56 cases (out of the 67 transplant cases) with three matching variables, including age (65 years), DIPSS score and cytogenetic risk category, using the GREEDY algorithm based on the Euclidean distance and the weighted sum of the absolute differences between the case and control matching factors; the last column of the table indicates the p values for the comparision of these two transplant and nontransplant cohorts. stratified by either the revised cytogenetic risk model, 13 or the dynamic international prognostic scoring system (DIPSS), 17 were compared to those of two separate nontransplant control groups; "control group A" (n 5 383) was selected from a larger database of PMF patients seen within the time frame of transplant dates and broadly matched with the transplant cohort by excluding patients older than the upper age limit for the transplant group and DIPSS low risk disease. A more stringent matching procedure was undertaken for selecting "control group B" where 56 controls were successfully matched with each of 56 cases (out of the 67 transplant cases) with three matching variables, including age (65 years), DIPSS score and cytogenetic risk per the revised system, 13 using the GREEDY algorithm based on the Euclidean distance and the weighted sum of the absolute differences between the case and control matching factors (http://www.mayo.edu/research/ departments-divisions/department-health-sciences-research/divisionbiomedical-statistics-informatics/software/locally-written-sas-macros).
The JMP® Pro 13.0.0 software from SAS Institute, Cary, North Carolina, was used for all other calculations.
| RE S U L TS
Sixty-seven patients with MF (median age 55 years; 66% males) were recruited from the Minnesota (n 5 29), Arizona (n 5 34) and Florida 
| D ISC USSION
In a recently published large and carefully conducted study of 233 MF patients who received HCT and were followed for a median of 8 years, 18 patients were risk assigned by both DIPSS 17 and the   FIG URE 2 Comparison of posttransplant survival data on 67 transplanted patients with myelofibrosis and overall survival data on a control group of 383 patients with primary myelofibrosis (PMF); the latter, referred to as "control group A", was selected from a larger database of PMF patients seen within the time frame of transplant dates and broadly matched with the transplant cohort by excluding patients older than the upper age limit for the transplant group and DIPSS low risk disease [Color figure can be viewed at wileyonlinelibrary.com] karyotype-inclusive DIPSS-plus. 19 Five-year survival in the particular study was 53% and univariate analysis suggested survival influence from age, HCT-specific comorbidity index (HCT-CI), type of MF, DIPSS, DIPSS-plus, unfavorable karyotype (based on older classification system), 19 and conditioning intensity 18 ; in multivariable analysis, the adverse survival effect of DIPSS-plus high risk disease, HCT-CI and the favorable impact of secondary MF were confirmed. In a separate analysis, the authors reaffirmed the additional prognostic value of unfavorable karyotype, 19 red cell transfusion dependency and anemia, in the setting of DIPSS-plus. 18 Possibly because of its smaller sample size, the was also previously recognized, although we did not confirm value in high risk patients. 20 Regardless, our main objective was to examine the impact of the revised cytogenetic risk stratification on transplant outcome. 13 The observed mitigating effect of HCT on high risk and unfavorable karyotype was encouraging and underline the power of immunotherapy, as opposed to drug therapy alone, in eradicating cytogenetically aggressive clones in MF. Whether or not the same holds true for adverse mutations, as has been previously suggested for other chronic myeloid neoplasms, 21 is currently under investigation 22, 23 and such information might also further clarify the interaction between DIPSS and transplant outcome. Finally, we recognize several limitations of the current study, including its retrospective design, relatively small sample size and the inclusion of post-ET and post-PV cases; the latter point was especially noteworthy considering the fact that our control group consisted entirely of patients with PMF and that both the revised cytogenetic risk stratification and DIPSS are based on PMF patients, although potentially applicable to secondary MF. 24 In conclusion, we show that allogeneic stem cell transplant in myelofibrosis overcomes the survival disadvantage associated with high and unfavorable risk karyotype and that patients receiving transplant live longer than their nontransplant counterparts, otherwise matched for age and
DIPSS
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